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Abstract
Background: Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the
skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. It is
estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex
virus, approximately 40% suffer from recurrent recurrent infections. This study evaluates the in
vitro skin permeation and penetration of penciclovir and acyclovir from commercialized creams for
the treatment of herpes labialis (cold sores), using non viable excised human abdominal skin
samples, which were exposed to 5 mg/cm2 of acyclovir 5% cream or penciclovir 1% cream.
Methods: After 24 h of cream application, excess cream was washed off and layers of stratum
corneum were removed by successive tape stripping. Amounts of active ingredients having
penetrated through the skin were measured, as well as the amounts in the washed-off cream, in
skin strips and creams remaining in the skin. Molecular modelling was used to evaluate physico-
chemical differences between the drugs. Western blot analysis enabled to determine whether the
marker of basal cells keratin 5 could be detected in the various tape strips.
Results: Application of penciclovir 1% cream yielded higher concentration of drug in the deeper
layers of the epidermis as well as a higher drug flux through the skin. Molecular modelling showed
two higher hydrophobic moieties for acyclovir. Presence of the basal cell marker keratin 5 was
underscored in the deeper tape strips from the skin, giving evidence that both drugs can reach their
target cells.
Conclusion: Penciclovir 1% cream has the tendency to facilitate the diffusion of the drug through
the stratum corneum into the deeper epidermis layers, in which it could reach the target basal cells
at effective therapeutical concentration. The small difference in the surface properties between
both molecules might also contribute to favour the passage of penciclovir through the epidermis
into the deeper basal cells.
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Background
Herpes simplex virus infection (HSV) is a common and
ubiquitous infection of the skin which causes mucocuta-
neous lesions called cold sores (herpes labialis) or fever
blisters. The vast majority of cold sores are due to herpes
simplex virus type 1 (HSV-1). It is estimated that approxi-
mately 80% of the population worldwide are carriers of
the Herpes simplex virus, approximately 40% suffer from
recurrent infections [1,2]. About 1% of sufferers have fre-
quent, i.e. monthly outbreaks of the latent herpes infec-
tion. These infections last for 4 to 10 days and can extend
up to 30 days in immunocompromised patients where
lesions may develop extensive necrosis [1]. Topical treat-
ment with antiviral drugs like acyclovir and penciclovir is
effective in shortening lesion duration and in relieving
pain, as has been shown in large randomized, double-
blind, vehicle controlled multi-centre clinical trials [1-4].
For best effect, antiviral drugs should be able to reach ther-
apeutic concentrations in basal epidermal cells, which are
the initial portal of entry to the virus spreading [5,6]. Con-
sequently, skin absorption is one of the most critical fac-
tors for successful therapy with a topical formulation for
the treatment of herpes labialis. The route of drug penetra-
tion across the stratum corneum, which is the main rate
limiting barrier to skin absorption [7], depends on the
properties of the respective drugs. Penciclovir has an addi-
tional hydroxyl group when compared to acyclovir (Fig-
ure 1), which became available as a generic drug in the
mid 1990s when its analogue penciclovir was launched
[8].
As the permeability properties of the stratum corneum
remain unchanged after removal from the body, a good
correlation has been observed between in vivo and in vitro
experiments with the same drug [9-11]. Thus, in vitro dif-
fusion through non viable human skin is a convenient
experimental tool to explore permeation characteristics of
a drug from its topical formulation.
The present study compared the in vitro skin distribution
and permeation of two commercialized creams contain-
ing 1% penciclovir or 5% acyclovir, both containing
approximately 40% propylene glycol. In vitro skin perme-
ation was assessed using human skin mounted in Franz-
type diffusion cells [12]. Following topical application of
5 mg/cm2 cream on excised human skin, drug permeation
into the receptor fluid of the diffusion chamber was meas-
ured after 24 h. At the end of the experiment drug levels in
the remaining skin were determined after removal of the
stratum corneum by tape stripping. Additionally, physico-
chemical differences between the drugs were investigated
by molecular modelling as this is a factor affecting dermal
absorption [13].
Methods
Products
Penciclovir cream 1% (10 mg/g penciclovir, Fenivir,
Novartis Consumer Health, Switzerland) was provided in
house and acyclovir cream 5% (50 mg/g acyclovir; Zovirax,
GlaxoSmithKline, United Kingdom) was purchased from
a Swiss pharmacy.
Penciclovir was provided in house and acyclovir was
bought from Sigma Chemicals (Switzerland).
Skin donor
After securing the appropriate consent the ethical commit-
tee of the International Institute for the Advancement of
Medicine (IIAM; United States) reviewed and approved
our application for request of human tissue to be used in
this study.
Full thickness human abdominal skin from 6 donors,
which was taken at autopsy, was provided cryopreserved
by IIAM. The skin was maintained frozen at -80°C. Prior
to use, the skin was thawed and the subcutaneous tissue
was carefully removed. The skin was dermatomed to 500
μm using a Wagner dermatome (model GB-231 Aesculap,
Germany), which enabled us to obtain split thickness tis-
sue constituted of the stratum corneum (10–20 μm), the
epidermis (100 μm) and part of the dermis (1200 μm)
[14,15].
Test of skin integrity
The permeation of tritiated water was evaluated to deter-
mine the skin integrity as described by Bronaugh [16].
Briefly, tritiated water (2.7 μCi/ml) was applied to the
skin surface. After 30 min, the radiolabelled water was
removed from the skin with cotton-wool tips. The recep-
tor phase (2 ml) was taken in order to measure the
amount of tritiated water (%) which permeated across the
skin, using a liquid scintillation counter. Formulations
were tested on skin samples having similar tritiated water
permeation values. Less than 1% of the applied dose of
tritiated water permeated through the skin.
Skin permeation
Skin permeation is the diffusion of the drug across the
skin layer into the receptor phase which represents blood
vessels. It was measured using a static Franz diffusion cell
of 1.75 cm2 for each skin sample exposed to the product
to be tested at 5 mg/cm2 simulating in use conditions and
in accordance to the test guideline OECD 428 [17].
Thawed human dermatomed skin samples were mounted
horizontally on the Franz cells, dermis side down. The
Franz cells were connected to a circulating water bath at
37°C, which yielded a tissue temperature of 32°C, com-
parable to the physiological temperature of the skin sur-BMC Dermatology 2009, 9:3 http://www.biomedcentral.com/1471-5945/9/3
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Chemical structures of acyclovir and penciclovir Figure 1
Chemical structures of acyclovir and penciclovir. Differences are indicated by arrows in the penciclovir structure.
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face. The receptor phase of PBS pH 7.4 (phosphate
buffered saline; 7.58 g/L Na2HPO4, 1.62 g/L NaH2PO4
and 4.4 g/L NaCl) contained within each diffusion cell
(approximately 8 ml) was mixed using a magnetic stirring
device to ensure appropriate homogenization of the
released drug in the acceptor phase throughout the exper-
iment. Samples of the receptor phase were collected at 24
h.
Skin penetration
The skin penetration was determined by measuring the
amount of drug residing in the various skin layers.
At the end of the 24 h after application skin samples were
washed off with soapy water and cotton-wool tips. The
top layer of the stratum corneum was removed with adhe-
sive tape (3 M Scotch n° 550) and analyzed separately.
Additional layers of the stratum corneum were removed
by up to 12 consecutive adhesive tape strips.
Following collection of all strips, the first and the second
strips were put into separate vials containing 10 ml of
water. Strips 3 up to 7 were pooled in the same vial con-
taining 20 ml of water. The remaining stripped skin was
minced and placed into a vial containing 15 ml water.
Mixtures were stirred overnight to ensure adequate extrac-
tion of the drug from the tape and the skin.
Sample analysis
Penciclovir and acyclovir content in the various samples
was measured by high performance liquid chromatogra-
phy (Agilent HP 1100) on a Waters Spherisorb® 5  μm
ODS2 (4.6 × 250 mm Analytical Cartridge PSS839540)
phase column at 35°C using a 1 ml flow rate of the
mobile phase of a mixture of methanol and 0.1 M pH 6.0
ammonium acetate buffer 1:10 (v:v) with UV detection at
254 nm. The sample was directly injected at a volume of
50 μl. Drug concentrations were determined from penci-
clovir or acyclovir standard curves between 10 and 50 ng/
ml generated with the pure compounds solubilized in PBS
at pH 7.4, which was the solvent used in the receptor
phase. Maximal soluble concentration in this solvent was
0.9 mg/ml for penciclovir and 0.7 mg/ml for acyclovir.
The retention time was respectively 6.7 min for penciclo-
vir and 5.1 min for acyclovir. The limit of quantitation
(LOQ) was 7 ng/ml for both drugs.
Molecular modelling
The characteristics of the penciclovir and acyclovir chemi-
cal structures were evaluated with an in house web based
CHEMINFORMATICS system using the CORINA pro-
gram. Generation and display of molecular surface prop-
erties enabled us to reveal those parts of the molecules
which are involved in hydrophobic or hydrophilic inter-
actions [18].
Western blot analysis
The skin sample from one donor was washed off with
soapy water and cotton-wool tips 24 h after the cream
application. The top layer of the stratum corneum was
removed with adhesive tape (3 M Scotch n° 550) and ana-
lyzed separately. Additional layers of the stratum corneum
were removed by up to 12 consecutive adhesive tape
strips. Following collection of all strips, the first and the
second strips were put into separate vials. Then pools of 3
to 4 strips were put in the same vial and the last strip was
placed separately in another vial. A volume of 250 μl/tape
strip of ice-cold lysis buffer (20 mM Tris-HCl; 2 mM
EGTA; 2 mM EDTA; 30 mM NaF; 30 mM Na4O7P2; 2 mM
Na3VO4; 1 mM [4-(2-Aminoethyl)benzenesulfonylfluo-
ride] (AEBSF); 10 μg/ml leupeptin; 4 μg/ml aprotinin; 1%
Triton X-100; pH 7.4) was added in the vial, which was
left for 10 min on ice and then vortexed. Supernatants
were collected and stored at -20°C overnight. Protein con-
centrations were measured by the BCA protein assay
(Pierce).
Ten μl of protein samples corresponding to 3 μg of protein
from tape strips lysat were separated by 10% SDS-PAGE
and transferred to polyvinylidene difluoride membranes
(Immobilon-P, Millipore, Bedford, MA). Membranes
were blocked by incubation with Trisbuffered saline (50
mM Tris, 150 mM NaCl) containing 0.2% (v/v) Nonidet
P-40 and 5% (w/v) nonfat dry milk for 30 min at room
temperature. Membranes were probed overnight at 4°C
with a monoclonal mouse anti-human Keratin 5 (Milli-
pore) antibody (1:20,000) and then with secondary
horseradish peroxidase-conjugated goat anti-human IgG
(1:20,000) (Transduction Laboratories, Lexington, KY)
for 1 h at room temperature. The membranes were
washed three times with Tris-buffered saline containing
0.2% (v/v) Nonidet P-40, and the antigen-antibody com-
plexes were detected by the Super Signal Substrate method
(Pierce). Identified protein bands were detected using a
video densitometer and ImageQuant software (Molecular
Dynamics, Sunnyvale, CA).
Statistical analysis
Unpaired Student t-test were performed to define a P
value between the pencyclovir cream and the acyclovir
cream. A P value of less than 0.05 was considered statisti-
cally significant.
Results
After the 24 h skin exposure time creams were washed off
from the skin and the acyclovir cream had 6-fold more
drug remaining in the washed-off cream than the penci-
clovir cream, with 245 μg/cm2 versus 40 μg/cm2, respec-
tively (not shown). These values represent the amount of
unabsorbed drug.BMC Dermatology 2009, 9:3 http://www.biomedcentral.com/1471-5945/9/3
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Cumulative amounts of each drug that had penetrated
into the skin are presented in Figure 2A. When acyclovir
was applied on the skin as 5% cream, the highest concen-
tration of acyclovir was found in strip 1 (0.88 μg/cm2)
while in the deeper successive strip (strip 2) the drug was
found at significantly lower concentration than penciclo-
vir from the 1% cream (Table 1; P = 0.002). In the pooled
strip 4.5 fold less acyclovir was found than for penciclovir.
This difference approached statistical significance (P =
0.07). Penciclovir from the 1% cream was found in the
first strip at 0.55 μg/cm2 while analysis of deeper succes-
sive strips revealed 0.29 μg/cm2 penciclovir in the 2nd strip
and 0.32 μg/cm2 in the pooled strip (from 3 strips up to 7
strips) (Figure 2A). The total concentration of drug found
in the pooled strips might include the entire epidermis in
accordance with the finding that after 3 h of experiment
duration the epidermis peels off with the stratum cor-
neum [19].
After 24 h the amount of penciclovir permeated through
the skin from the 1% cream was 3.4 fold more than acy-
clovir from the 5% cream (0.41 vs. 0.12 μg/cm2) (Table
1), leading to a flux of respectively 17 ng/cm2/h and 5 ng/
cm2/h as depicted in Figure 2B.
When the results were compare at equivalent dose 16.7
fold more penciclovir from the 1% cream permeated
through the skin than acyclovir, which was mainly limited
to the superficial skin layer. This difference show a trends
toward statistical difference (P = 0.06; Figure 1C and Table
1). Significantly more penciclovir were detected in deeper
strips such as strip 2 (P = 0.002) and pooled strips (P =
0.04). The difference between penciclovir and acyclovir
found in the dermis were close to statistical significance (P
= 0.06; Figure 1C and Table 1). Permeation through the
excised human skin reached 3.3% of the applied dose for
penciclovir and 0.2% for acyclovir (Table 1).
Molecular modelling enables to generate and display the
molecular surface properties such as electrostatic poten-
tial, lipophilicity potential or polar surface area revealing
parts of the molecule which are involved in hydrophobic
or electrostatic interactions or which may cause bioavaila-
bility difference. Thus this chemical modelling software
was used to compare acyclovir and penciclovir which are
known as hydrophilic drugs. As shown in Figure 3 the sur-
face charge distribution is very similar but the hydropho-
bicity distribution showed two areas of higher
hydrophobic moieties for acyclovir.
Discussion
Measurement of in vitro permeation across the split thick-
ness of human skin enables the evaluation of the passive
diffusion of the molecule into and across the skin to a sol-
ute reservoir, which simulates the capillaries of the der-
mis. Several factors influence the skin permeation among
which are the release of the drug from the formulation, its
penetration into the stratum corneum layers (10–20 μm)
and its diffusion through the stratum corneum into the
various epidermis layers (100 μm) and the dermis (1200
μm) to reach the circulation, as simulated by the fluid in
the reservoir.
When compared at an equivalent dose penciclovir from
the cream has the trend to have a higher transcutaneous
delivery than acyclovir. These results indicate a more effec-
tive release of penciclovir from the cream and across the
stratum corneum. Both formulations contain approxi-
mately 40% of propylene glycol (Acyclovir, 5% Zovirax
contains 40% and penciclovir 1% Pencivir contains 43%)
which is widely use as a co-solvent and penetration
enhancer [20]. This fatty alcohol, which diffuses well
through the stratum corneum [20] might alter the proper-
ties of this membrane leading to improved drug distribu-
tion especially for penciclovir, while further permeation
into the receptor fluid might be impaired for acyclovir.
This difference between these structurally related polar
molecules might be explained by the formulation itself
together with the presence of hydrophobic region in the
acyclovir structure as determined by the molecular model-
ling. This moiety may interact with hydrophobic structure
in the stratum corneum preventing further penetration. It
has been reported that increased lipophilicity is used to
reduce systemic absorption, which was reported for the
corticosteroids [21]. The hydrophilic feature of penciclo-
vir as shown in Figure 3 might not react with hydrophobic
structures, thus allowing penciclovir to be freely "drawn"
by the solvent between the corneocytes of the stratum cor-
neum within the hydrophilic region, constituting the
paracellular pathway [13,22].
The stripping technique enables measurement of drug
concentration in the stratum corneum by repeated appli-
cation of adhesive tape to the skin sample generally
between 10 to 15 times [14]. After a 3 h duration of this
experimental technique it has been reported that the stra-
tum corneum peels readily from the dermis including all
remaining epidermal layers [15,19]. It was questionable
whether under our experimental conditions, in which the
tape stripping was done 24 h after the product application
basal cells could be found in the tape strips. Knowing that
keratin 5 is specifically expressed in the basal cell of the
epidermis [23] a western blot analysis using a monoclonal
antibody against this protein was performed. As shown in
Figure 4 this technique produced a narrow, unique 60
kDa band in samples of pooled tape strips (on lane 3 and
4) and only very faint bands of similar size from samples
of tape strips 1, 2 and the last strip (on lane 5). This band
corresponds to the known molecular weight of keratin 5,
which is 58 kDa.BMC Dermatology 2009, 9:3 http://www.biomedcentral.com/1471-5945/9/3
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Comparison of drug concentration found in the tape stripping (A) and expressed as skin flux (B) or adjusted to the applied  dose (C) after application of Penciclovir 1% cream and Acyclovir 5% cream on excised human skin after 24 h Figure 2
Comparison of drug concentration found in the tape stripping (A) and expressed as skin flux (B) or adjusted to 
the applied dose (C) after application of Penciclovir 1% cream and Acyclovir 5% cream on excised human skin 
after 24 h. Values represent mean from 11 replicates with standard error of the mean.
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These results give evidence that basal cells were removed
during the tape stripping and were found mostly in the
deeper epidermal layer. Thus, concentrations per area of
penciclovir in pooled strips were converted into concen-
tration by volume with an estimate of epidermal depth of
100 μm [14], which yielded a 60 fold higher concentra-
tion than the in vitro inhibitory effect on HSV-1 with IC50
of 0.5–0.8 μg/ml as reported by Weinberg [24]. This sug-
gests penciclovir might be highly efficient in reducing the
viral load in the infected cells of the basal epidermal layers
when compared to the surface of epidermis represented
by the stratum corneum.
It is questionable whether the observed concentration dif-
ferences found between the two drugs at the different skin
layers might be due to the different intracellular half lives
of acyclovir (0.7–1 h) and penciclovir (10–20 h) [25-27].
As the excised skin was frozen before use this tissue might
not be viable lacking metabolism and enzymatic activity
[28]. Consequently, this excludes under experimental
conditions of the present study that viral thymidine
kinase could be active and could phosphorylate both
drugs which would be retained in cells [25]. In the future
it could be of interest to perform the study with fresh and
viable excised skin infected or not by HSV-1 to evaluate
the contribution of the viral enzymatic activity on the
drug bioavailability into the deeper epidermal layers
where the target cells are present.
Conclusion
In this in vitro model the passive diffusion of two
hydrophilic drugs from two comparable formulations
were studied showing both creams delivered the drug in
deeper epidermal skin layers where target basal cells were
localized as determined by the expression of the specific
keratin 5 protein. Molecular modelling enabled for the
first time to reveal difference between acyclovir and pen-
ciclovir on the surface properties. This observation might
Table 1: Comparison of the amount of antiviral drug found in the various skin compartments. 
Penciclovir cream (P) Acyclovir cream (A) Ratio (P/A) Statistics
μg/cm2 Mean s.e.m Mean s.e.m P value
Strip 1 0.55 0.16 0.88 0.3 0.6 0.42
Strip 2 0.29 0.06 0.06 0.03 4.9 0.002
Pooled Strips 0.32 0.12 0.07 0.04 4.5 0.07
Epidermis 1.15 0.35 1.01 0.04 1.1 0.32
Dermis (residual stripped skin) 0.10 0.04 0.07 0.04 1.4 0.63
Permeation through the skin (receptor phase) 0.41 0.19 0.12 0.10 3.4 0.18
Penciclovir cream (P) Acyclovir cream (A) Ratio
(P/A)
Statistics
% applied dose Mean s.e.m Mean s.e.m P value
Strip 1 1.15 0.41 0.30 0.11 3.8 0.06
Strip 2 0.61 0.16 0.02 0.01 29.1 0.002
Pooled Strips 0.67 0.31 0.02 0.01 32.3 0.04
Epidermis 2.4 0.9 0.3 0.1 7.0 0.3
Dermis (residual stripped skin) 0.17 0.07 0.02 0.01 9.1 0.06
Permeation through the skin (receptor phase) 0.68 0.33 0.04 0.03 16.7 0.06
Values represent mean from 11 replicates with standard error of the mean (s.e.m).
In vitro human skin percutaneous absorption of penciclovir and acyclovir from creams as cumulative permeation and when adjusted to the applied 
dose.BMC Dermatology 2009, 9:3 http://www.biomedcentral.com/1471-5945/9/3
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support that penciclovir has the tendency to have a higher
paracellular passage through the stratum corneum result-
ing in a tendency to reach higher concentration in deeper
epidermal layers.
As permeability properties of the stratum corneum
remained unchanged in non viable human skin the find-
ings of the present study might be extrapolated to in use
condition. By applying the cream at the prodormal stage,
when skin appears undamaged it can be postulated the
drug would be delivered at the level of basal cells where
the HSV-1 virus could be found in case of cold sore infec-
tion.
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Keratin 5 in tape strips from excised human skin 
treated with penciclovir 1% cream was detected by 
Western blot analysis. For the Strip 1 in lane 1, the Strip 2 
in lane 2 and the last Strip in lane 5 the signal of the 60 kD 
band was faint when compared to the pooled strips in lane 3 
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